PLECO THERAPEUTICS
Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM medications by focusing first on orphan cancer treatments. Current pre-clinical development activities at the firm are focused on the development of medicines for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.
PLECO THERAPEUTICS
Social Links:
Industry:
Clinical Trials Health Care Manufacturing Oncology Pharmaceutical
Founded:
2018-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.plecotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+31-61-132-5510
Email Addresses:
[email protected]
Total Funding:
17.3 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Maps Content Delivery Network ReCAPTCHA Google Universal Analytics Google Maps API Google Maps For Work
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NIIMBL
The NIIMBL mission is to accelerate biopharmaceutical manufacturing innovation, support the development of standards.
Oncora Medical
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hyloris Pharmaceuticals
Hyloris Pharmaceuticals investment in Series A - Pleco Therapeutics
OostNL
OostNL investment in Series A - Pleco Therapeutics
Netherlands Enterprise Agency
Netherlands Enterprise Agency investment in Series A - Pleco Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-09-05 | Pleco Therapeutics Announces the Appointment of Dr Henno Welgemoed as Chief Medical Officer |
Official Site Inspections
http://www.plecotherapeutics.com Semrush global rank: 13.14 M Semrush visits lastest month: 105
- Host name: 77.68.2.47
- IP address: 77.68.2.47
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Pleco Therapeutics"
About us - Pleco Therapeutics
Dan is a biologist specialized in bioinorganic chemistry of metals and free radicals in biological systems. He holds a PhD in Biochemistry from the Hebrew University in Jerusalem (Thesis: …See details»
Pleco Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +31-61-132-5510 Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM …See details»
Pleco Therapeutics - PitchBook
Pleco Therapeutics General Information Description. Developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy. The company aims to extend the life span and enhance the quality of life of …See details»
Press release - Pleco Therapeutics
Sep 6, 2022 For more information visit www.plecotherapeutics.com. Follow us on LinkedIn and Twitter [1] Worldwide AML incidence cases, Globocan registry [2] Cancer Stat Facts: …See details»
Pleco Therapeutics receives FDA Orphan Drug Designation
Jan 16, 2024 Julie Powell, Commercial: M: +44 (0) 7774 827205 E: [email protected]. Helen Pope, Media: M: +44 (0) 7879 818247 E: …See details»
Pleco Therapeutics Announces Expansion with the Incorporation …
Jul 26, 2022 NIJMEGEN, Netherlands and NEWARK, N.J., July 26, 2022 /PRNewswire/ -- Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments …See details»
Pleco Therapeutics receives FDA Orphan Drug Designation
Jan 16, 2024 Ivo Timmermans, MD MBA, Chief Executive Officer Ivo Timmermans, Chief Executive Officer, Pleco Therapeutics BV NIJMEGEN, The Netherlands, Jan. 16, 2024 …See details»
Pleco Therapeutics Announces €8.7m Strategic Partnership
Nov 10, 2021 Nijmegen, The Netherlands – 10 November 2021 – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel combination chelating agents to …See details»
Pleco Therapeutics Announces Expansion with the ... - BioSpace
Jul 26, 2022 Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer promoting cellular micro-environment, today …See details»
Pleco Therapeutics injected with €17.3 million to boost cancer ...
Sep 7, 2022 Dutch clinical stage biopharmaceutical company Pleco Therapeutics has raised €17.3 million in funding to develop a portfolio of cancer therapies. The Series A round was …See details»
Pleco Therapeutics Announces Final Close of its Series A Financing ...
NIJMEGEN, Netherlands, Sept. 6, 2022 /PRNewswire/ -- Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer …See details»
Press release - Pleco Therapeutics
Nov 10, 2021 For more information visit www.plecotherapeutics.com. Follow us on LinkedIn and Twitter About Hyloris Pharmaceuticals Hyloris is a specialty biopharma company focused on …See details»
Pleco Therapeutics receives FDA Orphan Drug Designation
Jan 16, 2024 NIJMEGEN, The Netherlands, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco …See details»
Pleco Therapeutics receives FDA Orphan Drug Designation
Jan 16, 2024 NIJMEGEN, The Netherlands, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...See details»
Press release - Pleco Therapeutics
Sep 5, 2023 For more information visit www.plecotherapeutics.com. Follow us on LinkedIn. For more information, please contact: Media. Sue Charles, Charles Consultants – sue@charles …See details»
Pleco Therapeutics Announces €8.7m Strategic Partnership with …
Nov 10, 2021 For more information visit www.plecotherapeutics.com. Follow us on LinkedIn and Twitter. About Hyloris Pharmaceuticals. Hyloris is a specialty biopharma company focused on …See details»
Press release - Pleco Therapeutics
Jan 16, 2024 Julie Powell, Commercial: M: +44 (0) 7774 827205 E: [email protected]. Helen Pope, Media: M: +44 (0) 7879 818247 E: …See details»
News - Pleco Therapeutics
Pleco Therapeutics is proud to announce the publication of a research paper, "Synthesis of Metal-Binding Amino Acids," in Organic & Biomolecular Chemistry.Authored by PhD-student.....See details»
Pleco Therapeutics receives FDA Orphan Drug Designation
Jan 16, 2024 Julie Powell, Commercial: M: +44 (0) 7774 827205 E: [email protected]. Helen Pope, Media: M: +44 (0) 7879 818247 E: …See details»